Compare Stocks: MOLN, MDXG, SGMT, and IRWD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$3.97 -2.6%	$4.18	$1.15 ▼ $5.78	$656.00M	0.2	3.07 million shs	503,187 shs
MDXG MiMedx Group	$4.52 -3.5%	$4.30	$3.03 ▼ $7.97	$658.11M	1.43	1.28 million shs	663,240 shs
MOLN Molecular Partners	$4.15 -4.6%	$4.14	$3.53 ▼ $5.36	$167.62M	1.09	4,678 shs	1,041 shs
SGMT Sagimet Biosciences	$11.38 +4.8%	$8.87	$4.50 ▼ $11.45	$707.38M	3.45	1.17 million shs	473,280 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	-2.40%	-7.71%	+0.49%	+12.12%	+266.67%
MDXG MiMedx Group	+0.21%	+2.86%	+9.60%	+26.83%	-34.27%
MOLN Molecular Partners	+1.52%	+1.93%	+4.00%	+10.41%	+13.51%
SGMT Sagimet Biosciences	+1.40%	-1.18%	+13.48%	+68.90%	+57.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$3.97 -2.6%	$4.18	$1.15 ▼ $5.78	$656.00M	0.2	3.07 million shs	503,187 shs
MDXG MiMedx Group	$4.52 -3.5%	$4.30	$3.03 ▼ $7.97	$658.11M	1.43	1.28 million shs	663,240 shs
MOLN Molecular Partners	$4.15 -4.6%	$4.14	$3.53 ▼ $5.36	$167.62M	1.09	4,678 shs	1,041 shs
SGMT Sagimet Biosciences	$11.38 +4.8%	$8.87	$4.50 ▼ $11.45	$707.38M	3.45	1.17 million shs	473,280 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	-2.40%	-7.71%	+0.49%	+12.12%	+266.67%
MDXG MiMedx Group	+0.21%	+2.86%	+9.60%	+26.83%	-34.27%
MOLN Molecular Partners	+1.52%	+1.93%	+4.00%	+10.41%	+13.51%
SGMT Sagimet Biosciences	+1.40%	-1.18%	+13.48%	+68.90%	+57.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	57.21% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	89.84% Upside
MOLN Molecular Partners	2.25	Hold	$8.38	101.76% Upside
SGMT Sagimet Biosciences	2.73	Moderate Buy	$27.96	145.70% Upside

Current Analyst Ratings Breakdown

Latest MOLN, MDXG, SGMT, and IRWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/9/2026	SGMT Sagimet Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$8.00 ➝ $18.00
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/4/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/27/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/27/2026	MDXG MiMedx Group	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $8.00
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
8/17/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
8/14/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRWD Ironwood Pharmaceuticals	$389.32M	1.68	$0.24 per share	16.20	($1.61) per share	-2.46
MDXG MiMedx Group	$418.63M	1.57	$0.54 per share	8.43	$1.73 per share	2.61
MOLN Molecular Partners	$5.65M	29.67	N/A	N/A	$2.40 per share	1.73
SGMT Sagimet Biosciences	$2M	353.66	N/A	N/A	$3.42 per share	3.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.16	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	112.90	26.56	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
MOLN Molecular Partners	-$74.41M	-$1.71	N/A	N/A	N/A	N/A	-68.36%	-54.82%	10/29/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)

Latest MOLN, MDXG, SGMT, and IRWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	MOLN Molecular Partners	-$0.45	-$0.44	+$0.01	-$0.43	N/A	N/A
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
MDXG MiMedx Group	0.07	5.33	4.79
MOLN Molecular Partners	N/A	7.27	7.27
SGMT Sagimet Biosciences	N/A	45.03	45.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRWD Ironwood Pharmaceuticals	N/A
MDXG MiMedx Group	79.15%
MOLN Molecular Partners	26.55%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
IRWD Ironwood Pharmaceuticals	9.30%
MDXG MiMedx Group	2.50%
MOLN Molecular Partners	5.93%
SGMT Sagimet Biosciences	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRWD Ironwood Pharmaceuticals	220	165.24 million	149.87 million	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
SGMT Sagimet Biosciences	8	62.16 million	55.01 million	Optionable

MOLN, MDXG, SGMT, and IRWD Headlines

Recent News About These Companies

Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 4.1% - Time to Buy?

16 minutes ago | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Upgraded at Cantor Fitzgerald

September 10 at 7:59 AM | marketbeat.com

Bank of New York Mellon Corp Invests $1.55 Million in Sagimet Biosciences Inc. $SGMT

September 10 at 3:27 AM | marketbeat.com

Cantor Fitzgerald initiates coverage of Sagimet Biosciences at overweight

September 9 at 12:44 AM | msn.com

Barclays upgrades Sagimet Biosciences to overweight from equal-weight

September 9 at 12:44 AM | msn.com

Sagimet Biosciences (NASDAQ:SGMT) Hits New 52-Week High - Here's Why

September 9 at 9:59 AM | marketbeat.com

Head to Head Analysis: Dianthus Therapeutics (NASDAQ:DNTH) versus Sagimet Biosciences (NASDAQ:SGMT)

September 8 at 4:15 AM | americanbankingnews.com

Seven Fleet Capital Management LP Buys Shares of 403,545 Sagimet Biosciences Inc. $SGMT

September 5, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Sets New 1-Year High - Should You Buy?

September 3, 2026 | marketbeat.com

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Financial Analysis: Valneva (NASDAQ:VALN) versus Sagimet Biosciences (NASDAQ:SGMT)

September 1, 2026 | americanbankingnews.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 31, 2026 | americanbankingnews.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts

August 31, 2026 | marketbeat.com

Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright

August 25, 2026 | marketbeat.com

Sagimet Biosciences Announces AURORA Phase 3 Acne Trial on Track to Begin Enrollment in Q4 2026

August 25, 2026 | quiverquant.comQ

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

August 25, 2026 | globenewswire.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | markets.businessinsider.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | globenewswire.com

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

August 17, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT

August 15, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Cut to "Sell" at Wall Street Zen

August 15, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, MDXG, SGMT, and IRWD Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

$3.96 -0.11 (-2.58%)

As of 01:15 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

MiMedx Group NASDAQ:MDXG

$4.51 -0.17 (-3.53%)

As of 01:15 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Molecular Partners NASDAQ:MOLN

$4.15 -0.20 (-4.57%)

As of 12:59 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Sagimet Biosciences NASDAQ:SGMT

$11.38 +0.52 (+4.78%)

As of 01:15 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, MDXG, SGMT, and IRWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, MDXG, SGMT, and IRWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, MDXG, SGMT, and IRWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, MDXG, SGMT, and IRWD Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

MiMedx Group NASDAQ:MDXG

Molecular Partners NASDAQ:MOLN

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, MDXG, SGMT, and IRWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, MDXG, SGMT, and IRWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, MDXG, SGMT, and IRWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, MDXG, SGMT, and IRWD Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

MiMedx Group NASDAQ:MDXG

Molecular Partners NASDAQ:MOLN

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools